Mansouri Yasaman, Goldenberg Gary
5 E 98th St, 5th Floor, New York, NY 10029-6574, USA.
Cutis. 2015 Mar;95(3):155-60.
Over the last decade, expanded understanding of psoriasis pathogenesis has led to the development of new systemic agents such as biological drugs that have revolutionized the treatment of psoriasis. Small molecule inhibitors also have been studied and offer patients options for oral administration. This article reviews recently approved and in-the-pipeline biologics (IL-17 inhibitors and IL-23 blockers) as well as small molecule inhibitors (phosphodiesterase 4 [PDE4] and Janus kinase [Jak] inhibitors).
在过去十年中，对银屑病发病机制的深入了解促使了新型全身用药的研发，比如生物药物，它们彻底改变了银屑病的治疗方式。小分子抑制剂也已得到研究，并为患者提供了口服给药的选择。本文综述了近期获批以及正在研发中的生物制剂（白细胞介素17抑制剂和白细胞介素23阻滞剂）和小分子抑制剂（磷酸二酯酶4 [PDE4]抑制剂和 Janus激酶[Jak]抑制剂）。
